Opthea OPT-302 Combo Outshines Lucentis Alone

At EURETINA 2019 Congress, the Australia based company Ophthea reported data that OPT-302 reduced areas of neovascularization by 38% more and decreased scarring by 39% more, compared to Lucentis alone … Source: FierceBiotech